GlassScriptPhysician profile
Stephen N Crowe
NPI 1285627141
$3,310.82
in general payments reported to CMS, 2019-2025
12 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.11 · 2021: $162 · 2022: $371 · 2023: $792 · 2024: $1,351 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.01 |
| Education | $243.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $2,399.26 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $369.58 | 2021-2024 | |
| Inspire Medical Systems, INC. | $113.75 | 2023-2025 | Inspire |
| Vanda Pharmaceuticals INC. | $110.49 | 2021-2025 | Fanapt |
| Avadel Cns Pharmaceuticals, LLC | $87.49 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $69.28 | 2020-2022 | |
| Eisai INC. | $56.57 | 2021-2022 | |
| Axsome Therapeutics, INC. | $34.11 | 2023 | Sunosi |
| 3b Medical, INC. | $22.17 | 2023 | Luna |
| Azurity Pharmaceuticals, INC. | $20.97 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $14.05 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.10 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.